<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862321</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.461</article-id><article-id pub-id-type="other">EPP0275</article-id><article-id pub-id-type="pii">S0924933824004619</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>The Role of Partial Agonists and Specifically Cariprazine in Dual Disorders</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Barab&#x000e1;ssy</surname><given-names>&#x000c1;.</given-names></name><xref rid="aff0989" ref-type="aff"/><xref rid="cor0322" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dombi</surname><given-names>Z. B.</given-names></name><xref rid="aff0989" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Csehi</surname><given-names>R.</given-names></name><xref rid="aff0989" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Djuric</surname><given-names>D.</given-names></name><xref rid="aff0989" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>N&#x000e9;meth</surname><given-names>G.</given-names></name><xref rid="aff0989" ref-type="aff"/></contrib></contrib-group><aff id="aff0989">
<institution>Gedeon Richter Plc</institution>., <city>Budapest</city>, <country>Hungary</country>
</aff><author-notes><corresp id="cor0322">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="436">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S215</fpage><lpage>S215</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824004619a.pdf"/><abstract><sec id="sec1933"><title>Introduction</title><p>The treatment of dual disorders, the co-occurrence of a major psychiatric disorder and a substance use disorder, represents a great challenge. Recent articles recommend antipsychotics with a dopamine partial agonism as first line treatment for these patients. Studies also postulate that drugs targeting the dopamine D3 receptors specifically might have an advantage, as these receptors are involved in drug-related reward, drug-seeking, and drug-intake behaviour. One compound that has both, partial agonist- and D3- activity is cariprazine.</p></sec><sec id="sec1934"><title>Objectives</title><p>To evaluate the real-world evidence of the effectiveness of cariprazine in patients with dual disorders.</p></sec><sec id="sec1935"><title>Methods</title><p>
We performed a systematic literature search on PubMed, looking for English language articles published between January 2017 - September 2023 with the following search terms: (cariprazine) AND (psychosis OR schizophrenia OR schizoaffective OR bipolar depression OR bipolar mania OR bipolar disorder OR major depressive disorder) AND (&#x0201c;substance use disorder&#x0201d; OR cocaine OR alcohol OR cannabis OR heroin OR &#x0201c;double diagnosis&#x0201d; OR &#x0201c;dual diagnosis&#x0201d;) NOT (animal OR rat OR mouse) NOT (review or meta-analysis). An additional targeted hand search of congress reports, posters, and case reports was also conducted.</p></sec><sec id="sec1936"><title>Results</title><p>
The search yielded 8 articles with 11 case reports. Mental health disorders included psychosis, schizophrenia, schizoaffective disorder, PTSD, and bipolar disorder while the abused substances were methamphetamine, cannabis, alcohol, and cocaine. All case reports described an improvement in both the symptoms of mental and substance use disorder with reduced craving and drug use and in some cases even ceasing drug use all together.</p></sec><sec id="sec1937"><title>Conclusions</title><p>In summary, evidence suggests that cariprazine seem to be a potential candidate for dual disorders as it improves symptoms of both mental and substance use disorders.</p></sec><sec id="sec1938"><title>Disclosure of Interest</title><p>&#x000c1;. Barab&#x000e1;ssy Employee of: Gedeon Richter Plc., Z. Dombi Employee of: Gedeon Richter Plc., R. Csehi Employee of: Gedeon Richter Plc., D. Djuric Employee of: Gedeon Richter Plc., G. N&#x000e9;meth Employee of: Gedeon Richter Plc.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>